Skip to main content

nivolumab (Opdivo®)


Status: In progress

As off-label monotherapy for patients with oesophageal and gastric cancer with high microsatellite instability or mismatch repair deficiency, used in palliative care setting as first line treatment.

Medicine details

Medicine name nivolumab (Opdivo®)
Formulation concentrate for solution for infusion
Reference number OW28

As above

Company Bristol Myers Squibb
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status In progress
AWMSG meeting date 09/07/2024
Date of issue TBC
Follow AWTTC: